Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population‐based testing program-Reference-Cited by-同舟云学术

Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population‐based testing program

Published:2020-10-22 Issue:1 Volume:15 Page:80-90
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Care Melanie¹²,McCuaig Jeanna²³⁴,Clarke Blaise⁵,Grenier Sylvie¹⁵,Kim Raymond H³⁶,Rouzbahman Marjan⁵,Stickle Natalie⁵,Bernardini Marcus Q⁷,Stockley Tracy L.¹⁵^ORCID

Affiliation:

1. Laboratory Medicine Program Division of Clinical Laboratory Genetics University Health Network Toronto Canada

2. Department of Molecular Genetics University of Toronto Toronto Canada

3. Familial Cancer Clinic Princess Margaret Hospital Cancer Centre University Health Network Toronto Canada

4. Lawrence S. Bloomberg Faculty of Nursing University of Toronto Toronto Canada

5. Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Canada

6. Division of Medical Oncology Department of Medicine University of Toronto Toronto Canada

7. Department of Gynecologic Oncology Princess Margaret Hospital Cancer Centre Toronto Canada

Funder

AstraZeneca Canada

Princess Margaret Cancer Foundation

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12817

Reference40 articles.

1. Ovarian cancer statistics, 2018

2. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

3. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

4. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

5. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients withBRCAmutated advanced high grade serous ovarian cancer: 10 year survival analysis;International Journal of Gynecologic Cancer;2024-03-28

2. Evaluation of Homologous Recombination Deficiency in Ovarian Cancer;Current Treatment Options in Oncology;2024-02

3. Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay;International Journal of Molecular Sciences;2023-12-04

4. Patient‐reported outcomes associated with reflex BRCA1 /2 tumor and subsequent germline panel genetic testing for high‐grade serous ovarian cancer;Journal of Genetic Counseling;2022-12-07

5. Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?;JCO Precision Oncology;2022-10